An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Experts say breakthrough HIV should still remain rare in those receiving ViiV Healthcare’s injectable Apretude as PrEP, an alternative to Truvada and Descovy.

This breakthrough gives great hope that we have a proven, highly effective prevention tool to protect people from HIV. There were 1.3 million new HIV infections globally in the past year.

A landmark breakthrough in HIV prevention received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effective that global health leaders had ...

In June, Gilead Sciences announced that its investigational antiretroviral drug lenacapavir prevented 100% of new HIV infections during a phase 3 trial conducted among cisgender women in Africa.

Lenacapavir's cost as HIV treatment in the United States in 2023 was $42,250 per new patient per year. Oral PrEP options, on the other hand, can cost less than $4 a month.

Montefiore strives to prevent the spread of HIV/AIDS and help patients with the disease live the longest, healthiest lives possible. For more than 30 years, we have cared for and treated patients ...

"We now have direct evidence of a major culprit in poor outcomes for some HIV-infected people, which is an important breakthrough in the fight against AIDS," said Ivona Pandrea, M.D., Ph.D ...